Literature DB >> 27236361

Systemic Thrombolysis for Ischemic Stroke after Antagonizing Dabigatran with Idarucizumab-A Case Report.

Niklas Schäfer1, Andreas Müller2, Ullrich Wüllner3.   

Abstract

We here describe our experience of systemic thrombolysis therapy for severe ischemic stroke in a patient taking dabigatran for atrial fibrillation. After administration of the monoclonal antibody fragment idarucizumab, the anticoagulative effects of dabigatran were efficiently antagonized and application of alteplase was safe and feasible in our patient. This case report may illustrate a novel treatment option in the neurological emergency setting.
Copyright © 2016 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Idarucizumab; atrial fibrillation; dabigatran; ischemic stroke; systemic thrombolysis

Mesh：

Substances：

Year:  2016        PMID： 27236361     DOI： 10.1016/j.jstrokecerebrovasdis.2016.05.006

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN： 1052-3057            Impact factor:   2.136


  11 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

2.  Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis.

Authors:  Felix C Ng; James Bice; Anne Rodda; Matthew Lee-Archer; Douglas E Crompton
Journal:  J Neurol       Date:  2017-02-06       Impact factor: 4.849

3.  Thrombolysis Following Heparin Reversal With Protamine Sulfate in Acute Ischemic Stroke: Case Series and Literature Review.

Authors:  Tamra Ranasinghe; Traci Mays; Jeff Quedado; Amelia Adcock
Journal:  J Stroke Cerebrovasc Dis       Date:  2019-07-17       Impact factor: 2.136

4.  Thrombolysis in Acute Ischemic Stroke after Idarucizumab for Dabigatran Etexilate Reversal in Elderly: A Case Report.

Authors:  Antonio Baule; Federico Cabigiosu; Bastianina Zanda; Alessandra Sanna; Claudia Mongili; Antonio Manca
Journal:  J Vasc Interv Neurol       Date:  2018-11

5.  Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report.

Authors:  Johannes Sebastian Mutzenbach; Slaven Pikija; Ferdinand Otto; Ursula Halwachs; Friedrich Weymayr; Johann Sellner
Journal:  Ann Clin Transl Neurol       Date:  2016-09-17       Impact factor: 4.511

6.  Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.

Authors:  Sergio Agosti; Laura Casalino; Enrico Rocci; Gabriele Zaccone; Eugenia Rota
Journal:  J Med Case Rep       Date:  2017-08-15

Review 7.  Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence.

Authors:  Slaven Pikija; Laszlo K Sztriha; J Sebastian Mutzenbach; Stefan M Golaszewski; Johann Sellner
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

8.  Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature.

Authors:  Senta Frol; Dimitrios Sagris; Janja Pretnar Oblak; Mišo Šabovič; George Ntaios
Journal:  Front Neurol       Date:  2021-06-03       Impact factor: 4.003

9.  Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report.

Authors:  Annemarie Gawehn; Yassine Ayari; Christian Heuschkel; Matthias Kaste; Pawel Kermer
Journal:  J Med Case Rep       Date:  2016-09-29

10.  Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations.

Authors:  Kazunori Toyoda; Hiroshi Yamagami; Masatoshi Koga
Journal:  J Stroke       Date:  2018-09-30       Impact factor: 6.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.